Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

The study underscored the intricate safety profile of tremelimumab and durvalumab in HCC patients, characterized predominantly by immune-mediated toxicities and significant gastrointestinal and hepatobiliary risks. Utilization of drugs necessitated meticulous patient selection and a multidisciplinary management approach to optimize patient outcomes and mitigate ADRs.